NIH Director's Blog: Drug Development
MAY 21, 2020
Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19. In the U.S.
The Pharma Data
FEBRUARY 12, 2022
The approval extends the current indication in China as add-on therapy in adults and children aged five years and older with active systemic lupus erythematosus (SLE). 8) despite standard therapy. Benlysta, combined with standard therapy, is indicated in adult patients with active lupus nephritis. About lupus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 26, 2021
The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE. positive anti-dsDNA and low complement) despite standard therapy. positive anti dsDNA and low complement) despite standard therapy. About the BLISS-LN study.
The Pharma Data
DECEMBER 23, 2020
It is approved in Argentina as the world’s first therapy for severe Chronic Fatigue Syndrome and is the only late-stage drug in the U.S. In addition, many survivors of the first SARS-CoV-1 epidemic in 2003 continued to report classic chronic fatigue-like symptoms after recovering from the acute illness. development pipeline for ME/CFS.
The Pharma Data
MAY 5, 2021
GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).
The Pharma Data
JULY 22, 2021
We believe patients, family members and physicians deserve the facts about the therapy and the process by which it was approved so they may make informed decisions. That was exemplified at its best with the COVID-19 vaccine development. ADUHELM is the first Alzheimer’s treatment approved since 2003. MS is another good example.
Drug Target Review
NOVEMBER 30, 2023
Then I was approached to co-found AC Immune in 2003. Food and Drug Administration for our Alzheimer’s vaccine candidate, ACI-24.060. COVID-19 has shown the revolutionary impact of vaccines. Our investigational active immunisation therapies could potentially delay or perhaps even prevent the onset of clinical dementia symptoms.
Expert insights. Personalized for you.
52 
Let's personalize your content